[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rechallenge\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rechallenge":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652599","pd-l1-inhibitor-rechallenge-after-immunotherapy-related-pneumonitis-in-patients-with-lung-cancer-100652599",false,"NCT07775820","PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer","Efficacy and Safety of PD-L1 Inhibitor Rechallenge After Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer: A Multicenter Real-World Study","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Histologically confirmed lung cancer.\n3. Development of checkpoint inhibitor pneumonitis after treatment with immune checkpoint inhibitor.\n4. Eastern Cooperative Oncology Group performance status of 0, 1, or 2.\n5. Provision of written informed consent.\n\nExclusion Criteria:\n\n1. Incomplete clinical information required for the study analyses.\n2. Considered unsuitable for participation by the investigator.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","This multicenter observational study will evaluate the safety and effectiveness of immune checkpoint inhibitor rechallenge in adults with lung cancer who developed checkpoint inhibitor pneumonitis.\n\nThe study will use both retrospective medical records and prospective follow-up data. Participants will not be assigned to any treatment by the study protocol. All treatment decisions will be made by the treating physicians as part of routine clinical care.\n\nParticipants will be classified into three groups according to their subsequent treatment: rechallenge with a PD-L1 inhibitor, rechallenge with a PD-1 inhibitor, or no immune checkpoint inhibitor rechallenge. The primary outcome is the recurrence of checkpoint inhibitor pneumonitis after rechallenge. Secondary outcomes include immune-related adverse events, progression-free survival, overall survival, objective response rate, and disease control rate at 24 weeks.\n\nApproximately 150 participants will be included across multiple study centers in China.",[24,25,26],"Lung Cancer","Rechallenge","Checkpoint Inhibitor Pneumonitis",[28,29,30,31,26,32,33],"Immune Checkpoint Inhibitor","PD-L1 Inhibitor","PD-1 Inhibitor","Immune Checkpoint Inhibitor Rechallenge","Immune-Related Adverse Events","Real-World Study","RECRUITING","2026-08-18",{"date":37,"type":38},"2026-08-20","ACTUAL",{"date":40,"type":38},"2025-10-20",{"date":42,"type":20},"2027-06-30",{"name":44,"class":45},"Nanfang Hospital, Southern Medical University","OTHER",5]